Osilodrostat
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endogenous Cushing's Syndrome
Conditions
Endogenous Cushing's Syndrome
Trial Timeline
Jun 13, 2022 → Aug 1, 2027
NCT ID
NCT05382156About Osilodrostat
Osilodrostat is a pre-clinical stage product being developed by Recordati for Endogenous Cushing's Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05382156. Target conditions include Endogenous Cushing's Syndrome.
What happened to similar drugs?
1 of 1 similar drugs in Endogenous Cushing's Syndrome were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06430528 | Pre-clinical | Recruiting |
| NCT05633953 | Pre-clinical | Completed |
| NCT05382156 | Pre-clinical | Active |
| NCT03606408 | Phase 2 | Completed |
Competing Products
2 competing products in Endogenous Cushing's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intervention/Treatment | Recordati | Approved | 36 |
| Osilodrostat | Recordati | Pre-clinical | 30 |